CASE BioMed and Wyss Zurich announce Collaboration

5506368c5fded48247b68dead1a595c6.jpg

Institutional Communication Service

14 June 2024

The Center of Advanced Studies on Entrepreneurship in BioMedicine (CASE BioMed) at Università della Svizzera italiana (USI) and the Wyss Zurich Translational Center (Wyss Zurich) have signed a Memorandum of Understanding (MoU) in June 2024 to enter in a long-term collaboration. The MoU expresses the mutual commitment of both parties to cooperate on life sciences entrepreneurship training programmes along a North-South alliance in Switzerland. While the existing entrepreneurship training programs that have been developed by CASE BioMed will continue to take place in Ticino, new offers will be jointly developed in Zurich.

CASE BioMed offers a series of leading-edge comprehensive advanced programmes – BioBusiness, MedTech Business, eHealth Business – providing young life sciences companies with the theoretical and project-based practical skills needed to develop, fund and market biomedical innovations. The training programmes are internationally recognised, with approximately 90% of the participants coming from other Swiss and European Universities. 60% of the students are from the Greater Zurich Area.

"For many years, we have been asked by our participants and instructors to also organise training programmes in Northern Switzerland. The collaboration with Wyss Zurich enables us to realise this opportunity in the environment of two world-class institutions, ETH Zurich and University of Zurich, that are in close contact with a dynamic and innovative life science startup ecosystem.I would like to take this opportunity to sincerely thank our long-standing and valuable Case BioMed Advisory board member Joerg Dogwiler, CEO of Congenius (https://congenius.ch) for mediating and providing such fundamental support for this important collaboration", commented Dr Heidrun Flaadt Cervini, Founder and Managing and Scientific Director of CASE BioMed.

Prof. Dr. Piero Martinoli, former president and honorary president of USI as well as Chairman of the CASE BioMed Advisory Board, summarizes: "We are very pleased that CASE BioMed's internationally recognized life sciences entrepreneurship programs are generating such a positive response from an outstanding organization like Wyss ZH , which represents the two leading institutions ETHZ and UZH. On the one hand, this collaboration will further strengthen the North-South educational policy axis and, on the other hand, it will also form a further bridge between the academic and business world. This is the achievement of many years of high-quality work by CASE BioMed under the leadership of director Dr. Heidrun Flaadt Cervini".

Dr Melanie Wiesel, Head of Operations at Wyss Zurich, added. "Our collaboration with CASE BioMed will boost existing offerings and support available in the German-speaking region of Switzerland. We are excited for our joint offerings and for life sciences researchers to reap the benefits of these programmes."

The collaboration between CASE BioMed and Wyss Zurich represents a mutual benefit for both parties and for entrepreneurship in life sciences across Switzerland.

About Center of Advanced Studies on Entrepreneurship in BioMedicine (CASE BioMed)

Università della Svizzera italiana (USI), with its Center of Advanced Studies on Entrepreneurship in BioMedicine (CASE Biomed) was, in 2010, the first academic institution in Switzerland to offer a series of leading-edge comprehensive advanced programmes – BioBusiness, MedTech Business, eHealth Business – providing young life sciences companies with the theoretical and project-based practical skills needed to develop, fund and market biomedical innovations. For more information, please visit www.biomed.usi.ch/en/study/center-advanced-studies-entrepreneurship-in-biomedicine

About Wyss Zurich Translational Center

The Wyss Zurich Translational Center (Wyss Zurich) is a joint accelerator of the University of Zurich and ETH Zurich (Swiss Federal Institute of Technology Zurich), which was made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. h.c. mult. Hansjörg Wyss. It was established to foster translational research focused on developing treatment protocols and clinical therapies, as well as novel technologies and intelligent systems, in the emerging fields of regenerative medicine, robotics, and medical devices/bionics. Wyss Zurich unites world-leading experts from both institutions in multidisciplinary teams, pooling their knowledge and expertise. For more information, please visit www.wysszurich.ch.

Contact Information:

Dr Heidrun Flaadt Cervini
Founder and Director
CASE BioMed
[email protected]

Dr Melanie Wiesel
Head of Operations
Wyss Zurich Translational Center
[email protected]

 

Sections

Events
15
July
2024
15.
07.
2024
17
July
2024
17.
07.
2024
19
July
2024
19.
07.
2024
22
July
2024
22.
07.
2024
30
July
2024
30.
07.
2024